Non-Hodgkin Lymphoma (NHL)

Latest News
June 27th 2024

Epcoritamab Gets Label Expansion for Difficult-to-Treat R/R Follicular Lymphoma

June 17th 2024

Polatuzumab Vedotin: Review Spotlights Its Use, Promise in DLBCL

June 14th 2024

Dr Catherine Diefenbach on the Evolving DLBCL Treatment Landscape

June 12th 2024

Case Reports: Managing DLBCL Associated With Papillary Thyroid Carcinoma

June 7th 2024

Obinutuzumab and Radiation Combo Shows Promise for Refractory DLBCL

Video Interviews
View All
February 8th 2024

Dr Ann LaCasce: T-Cell Engagers Have Improved DLBCL Outcomes, but Questions on Optimal Use Remain

June 9th 2023

Epcoritamab Approval Expands Treatment Armamentarium for DLBCL

Continuing Medical Education
June 29th 2024

Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care

1.0 Credits / Hematologic Cancer, Oncology
June 29th 2024

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
June 29th 2024

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

More News

dlbcl | Image Credit: laszlo-stock.adobe.com
June 3rd 2024

How the Tumor Microenvironment Affects DLBCL Prognosis, Treatment

Gayle Turim Dickstein
Further acknowledgement and study of the tumor microenvironment in diffuse large B-cell lymphoma (DLBCL) could eventually result in much more personalized—and effective—treatments.
Lymphoma word block image | Image Credit: © airdone - stock.adobe.com
May 27th 2024

Key Features of Rare Fibrin-Assisted Diffuse Large B-Cell Lymphoma

Kimberly Rath, PharmD
A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this condition.
Nurse holding older woman's hands | Image Credit: © Cecilie Arcurs/peopleimages.com - stock.adobe.com
May 24th 2024

IVIG Shows Promise in Protecting Older Patients With Lymphoma From COVID-19

Kimberly Rath, PharmD
Prophylactic intravenous immunoglobulin reduces COVID-19 infection rates in older patients with DLBCL with hypogammaglobulinemia undergoing reduced-intensity R-CHOP therapy.
Photomicrograph of a diffuse large B-cell lymphoma | Image Credit: ©DavidALitman - stock.adobe.com
May 16th 2024

Patient/Physician Teamwork: Treating a Rare Oral Presentation of DLBCL

Gayle Turim Dickstein
A very unusual case of lip-based diffuse large B-cell lymphoma (DLBCL) was treated successfully thanks to prompt diagnosis and chemotherapy treatments.
Health costs | Image credit: utah51 - stock.adobe.com
May 8th 2024

Study: Care Costs for R/R DLBCL Increase With Each Line of Therapy

Jared Kaltwasser
New therapies are helping patients, but are also driving up overall costs of care.
Lymphoma graphic | Image Credit: © MP Studion - stock.adobe.com
May 2nd 2024

Much-Improved Outcomes for Follicular Lymphoma Transformed to DLBCL in the Rituximab Era, Study Finds

Gayle Turim Dickstein
Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago.
IV chemotherapy | Image Credit: Aidman - stock.adobe.com
April 24th 2024

Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL

Luke Halpern
Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Doctors discussing a case | Image Credit: DelmaineDonson - stock.adobe.com
April 18th 2024

Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes

Kimberly Rath, PharmD
A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Liquid biopsy | Image Credit: ArtemisDiana - stock.adobe.com
April 13th 2024

Liquid Biopsy Whole-Genome Sequencing Optimizes MRD Detection in DLBCL

Luke Halpern
Using the newly created MAESTRO-Pool tool, whole genome sequencing revealed DNA that could be used to more effectively detect minimum residual disease (MRD) in patients who have diffuse large B-cell lymphoma (DLBCL).
Lymphoma diagnosis | Image Credit: Vitalii Vodolazskyi - stock.adobe.com
April 9th 2024

CAR T-Cell Therapy Effective in Older Patients With DLBCL

Luke Halpern
Overall survival and complete response rates were comparable across a younger and an older cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Malignant effusion cytology microscopic image of diffuse large B-cell lymphoma a type of non Hodgkin lymphoma | Image credit: David A Litman - stock.adobe.com
April 1st 2024

Older Patients With DLBCL Face Poor Overall Survival, High Costs With R-GemOx Treatment

Luke Halpern
Treatment with R-GemOx was associated with significant health care resource utilization, high costs surrounding treatment, and low overall survival in elderly patients with diffuse large B-cell lymphoma (DLBCL).
FDA | Image credit: wladimir1804 - stock.adobe.com
March 25th 2024

FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma, R/R DLBCL

Rose McNulty
The FDA issued complete response letters (CRLs) for the biologics license application for odronextamab in relapsed/refractory (R/R) follicular lymphoma and in R/R diffuse large B-cell lymphoma (DLBCL).
Magnified image of a cytokine storm | Image Credit: © nobeastsofierce - stock.adobe.com
March 19th 2024

Bispecific Antibodies Represent DLBCL Treatment Breakthrough

Luke Halpern
Analysis of single-agent, combination, and novel bispecific antibodies revealed a positive landscape of treatment for patients with diffuse large B-cell lymphoma (DLBCL).
Photomicrograph of a diffuse large B-cell lymphoma a type of non-Hodgkin lymphoma | Image Credit: DavidALitman - stock.adobe.com
March 15th 2024

Radiotherapy May Boost Survival for Certain Patients With DLBCL

Jared Kaltwasser
Patients had a lower risk of their diffuse large B-cell lymphoma (DLBCL) progressing if they had consolidative radiotherapy, a new report shows.
Patient in the hospital - Tyler Olson -stock.adobe.com.jpg
March 9th 2024

Predictive Model Can Assess Risk of Febrile Neutropenia in Patients Undergoing Chemotherapy for DLBCL

Luke Halpern
Investigators used a predictive model factoring in lymphopenia, elevated SIL2R level, extranodal involvement, and a positive hepatitis panel to determine risk for febrile neutropenia among patients with diffuse large B-cell lymphoma (DLBCL).
Case study graphic | Image credit: onephoto - stock.adobe.com
February 29th 2024

R-CHOP Leads to Positive Outcome in Rare Case of Collision Lymphoma

Jared Kaltwasser
The patient had both classical Hodgkin lymphoma and diffuse large B-cell lymphoma.
Diffuse large B-cell lymphoma - David A Litman - stock.adobe.com
February 28th 2024

Review Highlights Potential for Bispecific Antibodies in DLBCL

Luke Halpern
Investigators are optimistic about bispecific antibodies (BsAbs) for patients with diffuse large B-cell lymphoma (DLBCL), especially the possibility of combining different BsAbs with distinct targets for stronger treatment outcomes.
Doctor checking an older mans lungs | Image credit: DC Studio-stock.adobe.com
February 23rd 2024

Case of Primary Hepatic DLBCL Following COVID-19 Raises Questions About Possible Links

Jared Kaltwasser
Other viral infections, including Epstein-Barr virus and hepatitis C, have already been linked with primary hepatic lymphoma, the authors said.
Rituximab | Image credit: MQ-Illustrations - stock.adobe.com
February 20th 2024

Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL

Cameron Santoro
A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).
CAR T cell therapy rendering | Image Credit: © AIGen - stock.adobe.com
February 12th 2024

Meta-Analysis Highlights Differing CAR T Outcomes, Toxicities in Relapsed or Refractory DLBCL

Gwen Mergian
A real-world comparison of 2 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel and tisagenlecleucel—suggests the former is associated with better efficacy but higher toxicity.
A scientist working with microfluidic devices | Image credit: Наталья Евтехова - stock.adobe.com
February 4th 2024

Study: Microfluid Platform Can Help Screen Novel DLBCL Therapies

Jared Kaltwasser
The authors say their 3D model improves on results using traditional 2-dimensional approaches.
stem cell transplant text write on blackboard | Image credit: flytoskyft11 - stock.adobe.com
January 30th 2024

Retrospective Analysis Suggests Allo-HSCT Feasible for R/R DLBCL After CAR T Failure

Jared Kaltwasser
Among the 10 patients in the retrospective analysis, the median overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) was 21 months.
Patient and doctor | Image Credit: © DragonImages - stock.adobe.com
January 26th 2024

Case Report Highlights Case of Distinct DLBCLs in a Single Patient

Jared Kaltwasser
The authors suggest the phenomenon of 2 mutationally distinct diffuse large B-cell lymphomas (DLBCLs) might be more common than currently understood.
what we're reading logo
January 25th 2024

What We’re Reading: ACA Sign-Up Surge; Hospitals Fight Climate Change; Secondary Cancers, CAR T Link

AJMC Staff
A record 21.3 million people signed up for health insurance this year using the Affordable Care Act (ACA) marketplaces; nearly 80% of health care providers think it is important for their hospital to minimize its environmental impact; the FDA noted a potential link between CAR-T products and the development of T-cell cancer.
Data analytics | Image Credit: NicoElNino - stock.adobe.com
January 24th 2024

In DLBCL, Refining Patient Stratification an Ongoing Project

Jared Kaltwasser
New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states.
Ibrutinib | Image Credit: CLShebley
January 22nd 2024

Ibrutinib Plus R-CHOP Cost-Effective for Young Patients With ABC-DLBCL

Jared Kaltwasser
Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found.
Health care costs graphic | Image credit: wladimir1804 – stock.adobe.com
January 19th 2024

Study Highlights Treatment Patterns, Costs for DLBCL Not Treated With Stem Cell Transplant

Hayden E. Klein
Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.
EBO logo
January 12th 2024

Next Frontier of Precision Hematology Uses Patient Tissue to Find a Therapy Match

Mary Caffrey
Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R/R Follicular Lymphoma
January 8th 2024

Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R/R Follicular Lymphoma

Mary Caffrey
Lymphoma cells | Image credit: LASZLO - stock.adobe.com
September 22nd 2023

Salvage RT Shows Local Control in LBCL After CAR T-Cell Therapy Failure

Rose McNulty
Salvage radiation therapy (RT) showed efficacy in local control of relapsed or refractory large B-cell lymphoma (LBCL) following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy failure.
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo